Description of the medicine: Pioglitazone (Pioglitazone)
5 - [[4- [2- (5-Ethyl-2-pyridinyl) ethoxy] phenyl] methyl] -2,4-thiazolinedione hydrochloride.
Synonym: Actos, Actos.
Increases the sensitivity of target tissues to insulin and reduces the release of glucose from the liver.
Quickly absorbed, C max is 2 hours, T 3 - 3-7 hours (for metabolites - 16-24 hours); undergoes biotransformation in the liver with the formation of 2 active metabolites, excreted mainly with bile.
It is used (in monotherapy or in combination with sulfa drugs, metformin, insulin) for type II diabetes mellitus.
Assign inside (regardless of meal time), starting with a dose of 0.015-0.03 g (15-30 mg) 1 time per day, if necessary, increasing it to 0.045 g.
Possible side effects: hypoglycemic reactions, edema, anemia, allergic reactions.
Contraindications: the same as repaglinide.
Release form: tablets on 0,015 and 0,03 g (15 and 30 mg).